Canton Strategic Holdings, Inc. (CNTN) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Canton Strategic Holdings, Inc. (formerly Tharimmune, Inc.) has executed a strategic pivot from a clinical-stage biotechnology company to a digital asset treasury focused on the Canton Network and Canton Coin (CC). The company operates as a Super Validator on the Canton Network and provides "Locking-as-a-Service" (LAAS). The biotechnology subsidiary, Gravitas Life Sciences, Inc., was classified as discontinued operations and sold on July 17, 2026.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Three Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $1,495,859 | $1,495,859 |
| Net Loss (Continuing Ops) | $(63,650,148) | $(17,954,081) |
| Net Loss (Total) | $(66,598,023) | $(19,254,826) |
| Cash and Cash Equivalents | $37,241,568 | $37,241,568 |
| Digital Assets (Fair Value) | $523,353,752 | $523,353,752 |
| Total Assets | $564,570,386 | $564,570,386 |
| Total Liabilities | $109,667,774 | $109,667,774 |
| Stockholders' Equity | $454,902,612 | $454,902,612 |
Note: The company reported no revenue for the comparable periods in 2025. The significant net loss is primarily driven by non-cash unrealized losses on digital assets and stock-based compensation.
Material Changes vs. Prior Period
- Revenue Generation: The company generated $1.5 million in revenue for the first time, derived from network validation rewards ($191k) and LAAS services ($1.3M). There was no revenue in the prior year periods.
- Operating Expenses: General and administrative expenses surged to $37.9 million for the six months ended June 30, 2026, compared to $3.3 million in the prior year. This increase is largely attributable to $32.3 million in stock-based compensation related to strategic advisor warrants and RSUs.
- Digital Asset Volatility: The company recorded an unrealized loss of $38.7 million on digital asset holdings for the six-month period due to the fair value of Canton Coin falling below its weighted average cost basis.
- Capital Structure: The company raised approximately $91.2 million in net proceeds from financing activities, including a registered direct offering and at-the-market (ATM) sales, significantly increasing cash reserves from $12.0 million (Dec 31, 2025) to $37.2 million.
- Discontinued Operations: The biotechnology segment (Gravitas) is now reported as discontinued operations. The segment was sold in July 2026 for a promissory note of $3.5 million.
Guidance, Outlook, and Risks
Outlook: Management expects to fund operations through at least June 2027 based on current liquidity. Future revenue growth is tied to the unlocking of additional Super Validator weights under Canton Improvement Proposals (CIP 102 and CIP 114), with full weight eligibility expected by Q1 2028.
Risks and Contingencies:
- Asset Volatility: Financial results are highly correlated with the market price of Canton Coin. Significant price fluctuations could materially impact the balance sheet and net income.
- Regulatory Environment: Evolving regulations regarding digital assets, staking, and custody pose compliance risks.
- Going Concern: While liquidity is currently sufficient, the company's ability to continue as a going concern depends on the success of its digital asset strategy and access to capital markets.
- Derivatives: The company has begun entering into CC-denominated option contracts, introducing derivative risk.
Investor Verification Checklist
- Valuation of Digital Assets: Verify the fair value methodology for Canton Coin and the specific cost basis used to calculate the $38.7 million unrealized loss.
- Stock-Based Compensation: Review the terms of the Strategic Advisor Warrants and RSUs that drove the $32.3 million expense to understand future dilution and expense run-rates.
- Super Validator Milestones: Confirm the specific deliverables required to unlock the remaining 14.5 weight of Super Validator rewards and the timeline for revenue recognition.
- Gravitas Sale Terms: Review the terms of the $3.5 million promissory note received for the sale of Gravitas, including the 15% interest rate and maturity date (July 2029).
- Liquidity Runway: Assess the burn rate relative to the $37.2 million cash balance to validate the management's projection of funding through mid-2027.